全球萊姆病診斷市場 - 2022-2029

市場動態

由於萊姆病患病率的上升和診斷技術的進步，對萊姆病診斷的需求增加，推動了市場增長。

技術進步和不斷增加的新產品推出預計將推動市場增長。

全球萊姆病診斷市場的增長受到多種因素的推動，包括各種新的創新和產品發布，以及萊姆病患病率的上升。據萊姆病協會稱，萊姆病是世界上最常見的蜱傳細菌性疾病。

市場正在見證新的經過驗證的診斷測試的推出和批准，以準確診斷萊姆病。例如，2019 年 7 月，Zeus Scientific 宣布 Zeus ELISA Borrelia VlsE1/pepC10 IgG/IgM、Borrelia burgdorferi IgG/IgM、Borrelia burgdorferi IgM 和 Borrelia burgdorferi IgG Test Systems 等萊姆病診斷測試獲得食品藥品監督管理局的批准。管理局（美國食品和藥物管理局）。）有一個擴展的市場許可。這些診斷測試同時使用兩種□聯免疫吸附測定 (EIA)，而不是傳統的 EIA 和蛋白質印跡測試的兩步過程。

2020 年 2 月，DiaSorin 獲得了美國 FDA 的 Liaison LimeTotal Antibody Plus Assay 和 Liaison LimeTotal Antibody Plus Control Set 許可。該測定利用化學發光來檢測人血清和血漿樣品中針對伯氏疏螺旋體的 IgG 和 IgM 抗體。

此外，每個機構都為萊姆病診斷測試的開發提供資助。例如，2019 年 7 月，Enable Biosciences 獲得了隸屬於美國國立衛生研究院 (NIH) 的美國國家過敏和傳染病研究所 (NIAID) 的為期一年的 I 期資助，用於開發改進的萊姆病測試. 它獲得了 225,000 美元的小企業創新研究 (SBIR) 資助。

缺乏對萊姆病診斷的認識預計會阻礙市場增長。

預計對萊姆病診斷缺乏認識將阻礙預測期內的市場增長。因為很少有人知道萊姆病及其診斷。在農村地區，缺乏對該疾病及其診斷的知識正在限制市場增長。

行業分析

全球萊姆病診斷市場根據波特五力、監管分析、供應鏈分析、定價分析、產品創新和未滿足的需求等各種行業因素對市場進行了深入分析。 .

全球萊姆病診斷市場報告提供對大約 45 多個市場數據表、40 多個數字和 180 頁的訪問。

內容

第一章研究方法與範圍

• 調查方法
• 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

• 市場影響因素
  • 驅動程序
    • 萊姆病患病率上升
    • 不斷發展的技術進步
  • 限制因素
    • 對萊姆病的認識不足
  • 商機
  • 影響分析

第五章行業分析

• 波特五力分析
• 監管分析
• 供應鏈分析
• 定價分析
• 產品創新
• 未滿足的需求

第 6 章通過診斷技術

• 血清學檢測
• 尿抗原檢測
• 淋巴細胞轉化試驗
• 免疫熒光染色
• 核酸檢測
• 其他

第 7 章按應用程序

• 醫院
• 公共/私人檢驗機構
• 醫務室

第 8 章按地區

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 意大利
  • 西班牙
  • 其他歐洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 其他亞太地區
• 中東和非洲

第 9 章競爭格局

• 主要發展和戰略
• 公司份額分析
• 按產品類型進行基準測試
• 值得關注的重點公司列表

第 10 章公司簡介

• 雅培實驗室
  • 公司概況
  • 按產品類型劃分的產品組合和內容
  • 主要亮點
  • 財務摘要
• T2 Biosystems, Inc.
• Bio-Rad Laboratories, Inc.
• Alere Inc.
• Roche Diagnostics International Ltd.
• Graphene Frontiers, LLC
• Covance Inc.
• Immunetics Inc.
• GlaxoSmithKline Pharmaceuticals Ltd.
• Boulder Diagnostics Inc.

第11章 全球萊姆病診斷市場-DataM

Market Overview

Lyme Disease Diagnostics Market size was valued US$ 2.53 billion in 2021 and is estimated to reach US$ 4.27 billion by 2029, growing at a CAGR of 8.9% during the forecast period (2022-2029).

Lyme disease diagnostics are the diagnostic tests used for diagnosing the signs & symptoms, and other diseases such as neurologic, cardiac symptoms associated with Lyme disease. These diagnostic tests identify the antibodies produced by the immune system in response to the infection. Lyme disease diagnostics predicts the likelihood of whether the patient is exposed to infected blacklegged ticks.

Market Dynamics

The market growth is driven by the rising demand for Lyme disease diagnosis due to the rising prevalence of Lyme disease as well as technological advancements in diagnostics.

Increasing advancements in technology and introduction of novel products are expected to drive market growth.

The global Lyme disease diagnostics market growth is driven by several factors, such as various new innovations and products release in market and rising prevalence of Lyme disease. According to the Lyme Disease Association, Lyme Disease is the most common tick-borne bacterial infection in the world.

The market is witnessing the launch and clearance of new validated diagnostic tests for accurate diagnosis of Lyme Disease. For instance, in July 2019, Zeus Scientific had received the expanded market clearance from Food and Drug Administration (US FDA) for its diagnostic tests such as Zeus ELISA Borrelia VlsE1/pepC10 IgG/IgM, Borrelia burgdorferi IgG/IgM, Borrelia burgdorferi IgM and Borrelia burgdorferi IgG Test Systems for Lyme disease. These diagnostic tests include the concurrent use of two enzyme immunoassays (EIA), instead of the existing two-step process requiring an initial EIA test followed by a Western Blot protein test.

In February 2020, DiaSorin had received clearance from the Food and Drug Administration (US FDA) for Liaison Lyme Total Antibody Plus assay and Liaison Lyme Total Antibody Plus Control Set. This assay uses chemiluminescence to detect lgG and IgM antibodies to Borrelia burgdorferi in human serum and plasma samples.

Moreover, the organizations are providing grants for the development of Lyme disease diagnostic tests. For instance, in July 2019, Enable Biosciences had received the award of one-year Phase I Small Business Innovative Research (SBIR) grant for USD 225,000 from the National Institute of Allergy & Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) for the development of an improved Lyme disease test.

Scarcity of awareness associated with Lyme disease diagnostics is expected to hamper the market growth.

Unawareness about the Lyme disease diagnostic is expected to hinder the market's growth over the forecast period. As few people know about the disease and its diagnosis. In rural areas people lack knowledge related to disease and its diagnosis hence restrains the growth of market.

Industry Analysis

The global Lyme disease diagnostics market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Product Innovation, Unmet Needs.

Segment Analysis

Diagnostic technology segment is expected to hold the largest market share in global lyme disease diagnostics market

The global Lyme disease diagnostics market is segmented based on diagnostic technology as a serological test, urine antigen tests, lymphocytic transformation test, immunofluorescent staining, nucleic acid test, and others. The serological test segment accounts for the highest market share due to the high usage of Serological tests for diagnosing Lyme disease. This test involves the initial screening assay for the detection of antibodies leading to the development of Lyme Disease. Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot are the commonly used serological tests for Lyme Disease diagnosis.

The urine antigen tests segment is expected to have positive market growth due to growing research and development activities for urine antigen tests for the diagnosis of Lyme Disease. Ceres Nanosciences had developed the urine-based Nanotrap Lyme Antigen test for detecting Lyme disease. The urine antigen tests segment is dominated by the presence of the development of urine antigen tests products that have received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). For instance, In Jun 2022, Adaptive Biotechnologies decided to interpret adaptive immune structure genetics to clinical device for the diagnosis of disease using T-Detect Lyme.

Further, the market is also classified based on application into hospitals, public/private laboratories, and physician's offices. The hospital segment is expected to witness the highest market growth due to Lyme Disease diagnostic tests' high usages with the rising hospitalization cases.

The public/private laboratories segment is expected to have positive market growth due to the increase in the number of public/private laboratories for diagnosing Lyme Disease. The majority of the public/private laboratories are providing Lyme disease testing using urine or other body fluids and serological tests.

Geographical Analysis

North America region holds the largest market share in the global Lyme disease diagnostics market

By region, the global Lyme disease diagnostics market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, the North American region dominated the global Lyme disease diagnostics market due to the high prevalence of Lyme Disease. According to the Centres for Disease Control and Prevention (CDC), approximately 300,000 people are suffering from Lyme Disease in the United States every year. There are rising government and private institutes initiatives to treat and diagnose Lyme Diseases in countries in the region. There are a majority of the companies developing Lyme Diseases diagnostics. Several institutes have increased their focus on developing novel diagnostic tests. For instance, in November 2019, the National Institutes of Health (NIH) had planned a five-year strategic plan to accelerate research initiatives leading to better prevention, diagnosis, and treatment of tick-borne diseases. In March 2020, a leading sponsor of Lyme disease research in the United States, Bay Area Lyme Foundation had opened the San Diego collection site of the Bay Area Lyme Foundation's Lyme Disease Biobank to provide researchers with blood and urine samples from people with early Lyme Disease from multiple endemic regions across the country.

Europe is expected to witness positive market growth due to the drastic increase in Lyme Disease cases. Over the last decade, the incidence of cases of Lyme Disease has increased by three times in Europe. The market is witnessing the development of novel diagnostic tests with technological advancement. These emerging diagnostic tests would help in the accurate diagnosis of Lyme Disease.

Competitive Landscape

The global Lyme disease diagnostics market is fragmented with the presence of many local and international players. Abbott Laboratories, Bio-Rad Laboratories, Affymetrix, Inc., Roche Diagnostics, T2 Biosystems, and GlaxoSmithKline Pharmaceuticals are the leading companies with a significant market share.

Technology advancement, product diversification, market expansion, and new product launches intensify the market competition. For instance, T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease.

Ceres Nanosciences had developed the urine-based Nanotrap Lyme Antigen test for detecting Lyme disease. This Nanotrap enrichment technology would detect Lyme antigens in patient urine at the early stages of the disease. This technology would use Nanotrapto uses hydrogel particles to capture, preserve, and enrich target analytes and allow the more sensitive detection of low abundance molecules.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to increase the demand for Lyme Disease Diagnostics and their expansion across the globe. For instance, in June 2019, Qiagen and DiaSorin entered into the collaboration to develop an ultra-sensitive QuantiFERON-based diagnostic test to detect Lyme disease early. QuantiFERON technology comprises a sample collection component with its assay stimulus/initiation and a read-out component to measure the stimulus's signals. This component would be run on DiaSorin's LIAISON family of fully-automated analyzers.

In July 2019, PerkinElmer had entered into the collaboration with and EverlyWell for accelerating the innovation in and accessibility of consumer-initiated health testing, by adding PerkinElmer's CLIA-certified and CAP-accredited lab facilities to EverlyWell's network of laboratory providers. The first offerings resulting from this collaboration include the Lyme disease and food sensitivity tests for which PerkinElmer would provide the expertise behind EverlyWell's panels.

Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

PLEX-ID: It is molecular diagnostic technology based which integrates mass spectrometry and PCR technology and identifies and characterises wide range of micro-organisms.

Key Developments: In Oct 2020, Abbott got emergency use authorization for their COVID-19 IgM antibody blood test from the FDA.

The global Lyme disease diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. Rising prevalence concerning Lyme disease
    • 4.1.1.2. Growing Technological Advancement
  • 4.1.2. Restraints:
    • 4.1.2.1. Scarcity of awareness about Lyme disease
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Regulatory Analysis
• 5.3. Supply Chain Analysis
• 5.4. Pricing Analysis
• 5.5. Product Innovations
• 5.6. Unmet Needs

6. By Diagnostic Technology

• 6.1. Introduction
  • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Technology Segment
  • 6.1.2. Market Attractiveness Index, By Diagnostic Technology Segment
• 6.2. Serological Test
  • 6.2.1.1. Introduction
  • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 6.3. Urine Antigen Tests
• 6.4. Lymphocytic Transformation Test
• 6.5. Immunofluorescent Staining
• 6.6. Nucleic Acid Test
• 6.7. Others

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 7.1.2. Market Attractiveness Index, By Application Segment
• 7.2. Hospitals
  • 7.2.1.1. Introduction
  • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Public/Private Laboratories
• 7.4. Physician's Office

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Technology
  • 8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Technology
  • 8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Italy
    • 8.3.5.5. Spain
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Technology
  • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Technology
  • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. Australia
    • 8.5.5.5. Rest of Asia Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostic Technology
  • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape

• 9.1. Key Developments and Strategies
• 9.2. Company Share Analysis
• 9.3. Product Types Benchmarking
• 9.4. List of Key Companies to Watch

10. Company Profiles

• 10.1. Abbott Laboratories
  • 10.1.1. Company Overview
  • 10.1.2. Product Type Portfolio and Description
  • 10.1.3. Key Highlights
  • 10.1.4. Financial Overview
• 10.2. T2 Biosystems, Inc.
• 10.3. Bio-Rad Laboratories, Inc.
• 10.4. Alere Inc.
• 10.5. Roche Diagnostics International Ltd.
• 10.6. Graphene Frontiers, LLC
• 10.7. Covance Inc.
• 10.8. Immunetics Inc.
• 10.9. GlaxoSmithKline Pharmaceuticals Ltd.
• 10.10. Boulder Diagnostics Inc.

LIST NOT EXHAUSTIVE

11. Global Lyme Disease Diagnostics Market - DataM

• 11.1. Appendix
• 11.2. About Us and End User
• 11.3. Contact Us